Corbus Pharmaceuticals (CRBP) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($253.5 million vs $104.1 million), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | VCRE |
|---|---|---|
| Share price | $5.38 | $9.00 |
| Market cap | $104.06M | $253.48M |
| 1-day change | +2.09% | +2.04% |
| YTD return | -35.26% | — |
| 1-year return | -60.73% | — |
| 5-year return | -82.78% | — |
| EPS (TTM) | $-6.11 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.56 | $17.80 |
| 52-week low | $5.13 | $7.88 |
| Distance from 52-week high | -73.83% | -49.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +532.53% | +268.44% |
| Average volume | 756.54K | 16.22K |
| Shares outstanding | 19.34M | 28.16M |
| Employees | 36 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vicore Pharma AB is about 2.4 times larger than Corbus Pharmaceuticals by market value ($253.48M vs $104.06M).
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
CRBP vs VCRE FAQ
Which is bigger, Corbus Pharmaceuticals or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $253.48M compared with $104.06M for Corbus Pharmaceuticals (CRBP).
Are Corbus Pharmaceuticals and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.